Clinical trials: Epidermis
HR+/HER2- Advanced Breast Cancer, Targeted Therapy
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
To explore the efficacy and safety of chidamide combined with endocrine in phosphoinositide-3-kinase,catalytic,alpha gene(PI3KCA) wild type hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-)…
- Trial name
- NCT05983107
- Testing
- Everolimus, Chidamide, Endocrine therapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Healthy
Micropore Closure Kinetics at Various Body Sites
The study to be performed will define the rate of skin barrier recovery following micropatch application to the skin on the upper arm, volar forearm, and abdomen in healthy subjects.
- Trial name
- NCT03657277
- Testing
- Micropatch
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Port Wine Stain
Dynamic Epidermal Cooling During Pulsed Dye Laser Treatment of Port Wine Stain Birthmark at High Fluences
The purpose of the study is to improve the efficacy of pulsed dye laser treatment of port wine stain birthmarks. Involvement in the protocol will involve formal documentation of the level of treatment pain, duration of…
- Trial name
- NCT00540371
- Testing
- Port wine stain Birthmark
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Burn Degree Second, Burn Degree Third
The Use of Cultured (Dermal) Epithelial Autografts in Severely Burned Patients
The Swisskera project is a multicenter follow-up study at the three Swiss burn centers evaluating long-term outcomes after burn wound coverage with lab-grown epithelial grafts, specifically cultured epithelial autograft (CEA)…
- Conditions
- Burn Degree Second, Burn Degree Third, Skin Transplantation, Full Thickness Skin Defects
- Trial name
- Swisskera (NCT07415577)
- Testing
- Standard of Care (SOC)
- Where
- 3 sites in Switzerland
- Volunteers
- 236 people
- Sponsor
- University Children's Hospital, Zurich
Breast Cancer Stage I, Breast Cancer Stage II
Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study
Global cancer statistics by world region for the year 2022 estimated breast cancer the 2nd cause of new cancer cases (11.6%). (1) Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth…
- Conditions
- Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Trial name
- NCT06950671
- Where
- Egypt
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Rahma Esam Salama Esawi
Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT02917993
- Testing
- Itacitinib, Osimertinib
- Where
- 31 sites in United States, South Korea and 2 more
- Volunteers
- 59 people
- Sponsor
- Incyte Corporation
Advanced Breast Cancer, Metastatic Breast Cancer
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
NUV-422-03 is a randomized, non-comparative Phase 1/2 dose escalation and expansion study designed to evaluate the safety and efficacy of NUV-422 in combination with fulvestrant relative to NUV-422 monotherapy and fulvestrant…
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma
- Trial name
- NCT05191004
- Testing
- NUV-422, Fulvestrant
- Where
- 5 sites in United States
- Sponsor
- Nuvation Bio Inc.
Metastatic Malignancies
Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy
Angiogenesis inhibitors and EGFR inhibitors not only have anti tumor activity but also modify physiological processes. This study evaluates effects on vascular function, endocrine function and metabolism.
- Trial name
- Mabtornib (NCT00657098)
- Where
- Netherlands
- Volunteers
- 73 people
- Sponsor
- University Medical Center Groningen
Breast Cancer
Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
The goal of this clinical trial is to learn if an artificial intelligence model will be able to select patients with advanced breast cancer who may respond to a second cyclin-dependent kinase 4/6 (CDK4/6) inhibitor after they…
- Trial name
- AIM-BRIGHT (NCT07227233)
- Testing
- A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of California, San Diego
Neoplasm Metastasis, Colorectal Cancer
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor…
- Trial name
- OPUS (NCT00125034)
- Testing
- Cetuximab, Oxaliplatin
- Where
- 78 sites in Austria, Belgium and 11 more
- Volunteers
- 344 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Healthy Skin
Effect of a Basic Skin Care Product on the Structural Strength of the Skin
The main aim of this study is to investigate in a suction blister model, whether the use of a basic skin care formulation increases the mechanical integrity/adhesion of the dermo-epidermal junction.
- Trial name
- NCT03625167
- Testing
- Treatment with petrolatum
- Where
- Germany
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Prof. Dr. Jan Kottner
Non-small Cell Lung Cancer
Tarceva. ICORG 08-41
The aim of this study is to determine prospectively the value of a recently identified proteomic signature in identifying those patients with lung cancer, who are likely to benefit from and respond favourably to erlotinib…
- Trial name
- NCT01721252
- Where
- 7 sites in Ireland
- Volunteers
- 200 people
- Sponsor
- Cancer Trials Ireland
Non-small-cell Lung Cancer
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
The purpose of this study is to evaluate the overall response rate and disease free survival for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation.
- Trial name
- NCT01843647
- Testing
- Icotinib, Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Vitiligo
A Novel Surgical Method in the Treatment of Unstable Vitiligo
Vitiligo is a complex disease causing a selective, often progressive, loss of functioning melanocytes from epidermal basal layer resulting in white patches on the skin and occasionally mucosae.
- Trial name
- NCT03013049
- Testing
- Non cultured epidermal cell suspension, Non cultured dermal cell suspension
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hypophosphatemia, Hypophosphatemic Rickets
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
A 52 week, open label trial to assess the safety and efficacy of KRN23, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome(ENS) and associated hypophosphatemic rickets A 26 weeks…
- Conditions
- Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic
- Trial name
- NCT03581591
- Testing
- Burosumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Redwood Dermatology Sciences
Breast Cancer
A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
The purpose of the study is to evaluate dose limiting toxicity (DLT), investigate the tolerability and safety of eribulin mesylate with trastuzumab combination therapy, and estimate the recommended dose.
- Trial name
- NCT01432886
- Testing
- E7389
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Eisai Co., Ltd.
Gastric Cancer, Stomach Cancer
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.
- Trial name
- NCT00857246
- Testing
- Cetuximab, Irinotecan, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
The investigators' aim is to study the effects of mechanical expression of meibomian glands on eyelid disease, ocular surface health in the subacute phase of SJS/TEN.
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis
- Trial name
- NCT05145959
- Testing
- Maskin Probe
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma
- Trial name
- NCT02365662
- Testing
- ABBV-221
- Where
- 5 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- AbbVie
HER2+ Cancer
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901
HER2 is a protein that is over expressed in 20-30% of breast cancers. It is also found associated with lung, gastric, ovarian, and pancreatic cancers.
- Trial name
- NCT01526473
- Testing
- AVX901
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Kim Lyerly
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.